Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial - de Alarcon, P A; Matthay, K K; London, W B (Lancet Child Adolesc Health, 2018)